View Older Stories View More Recent Stories
-
Roth Sees Regeneron/Sanofi Alirocumab Phase 2 Results as Positive; Maintains 'Buy' Rating (REGN)
-
Clean Diesel (CDTI) Announces $6.9M Equity Raise
-
CDTi to Raise Approximately $6.9 Million
-
Roth Capital Positive on Palatin (PTN) Granting Bremelanotide Extension
-
Roth Raises PT on Regeneron (REGN) to $382; ODYSSEY MONO, Alirocumab Data Bolsters Positive Outlook
-
Regeneron Pharma (REGN) PT Raised to $382 at Roth Capital
-
Roth Boosts PT on Curis (CRIS) to $10; '427 Overhang Now Lifted
-
Notable 52-Week Highs and Lows of the Day 03/28: (AA) (ELY) (INVN) High; (EXEL) (SPEX) Low
-
Notable Analyst Rating Changes 03/28: (SCTY) (CTSH) (INVN) Upgraded; (PNW) (CIEN) (PCG) Downgraded
-
Cytokinetics (CYTK) Starts COSMIC-HF Phase II Enrollment; BENEFIT-ALS Still in Focus - Roth
-
Endocyte (ECYT) Prices 4.5M Share Offering at $21
-
Roth Capital Upgrades InvenSense (INVN) to Buy
-
Endocyte, Inc. Prices Public Offering of Common Stock
-
Cytokinetics' (CYTK) Initiation of CK-2127107 Phase I is Positive Development - Roth
-
Applied Genetic Technologies (AGTC) IPO Opens Higher
-
Alt-Energy Names Show Early Gains (FCEL)(BLDP) (PLUG)
-
Roth Starts Active Power (ACPW) at Buy; Refocused Company Should See N-T Gains
-
Applied Genetic Technologies (AGTC) IPO Prices at $12, Below Range
-
Roth Capital Starts Active Power (ACPW) at Buy
-
AGTC Announces Pricing of Initial Public Offering
-
RGS Energy's (RGSE) New Financing Strategy Could Provide Upside; Roth Boosts PT to $6
-
American Apparel (APP) Prices 61M Common Offering at 50c/Share
-
Notable Analyst Rating Changes 03/25: (SOL) (RAX) (PCAR) Upgraded; (HIMX) (PHM) (ACI) Downgraded
-
Pre-Open Stock Movers 3/25: (GALT) (ECYT) (RAX) Higher; (IDN) (HIMX) (GIII) Lower (more...)
-
Roth Upgrades ReneSola (SOL) to Buy; Sees Outperformance Continuing on Strong Differentiation
-
American Apparel (APP) Commences $30.5M Cmmon Stock Offering
-
Roth Capital Upgrades Silvercrest Mines (SVLC) to Buy
-
Roth Capital Upgrades ReneSola Ltd. (SOL) to Buy
-
Stronger-than-Expected FY13 Results Set Rexahn Pharma (RNN) Up for Promising FY14 - Analyst
-
Roth Cuts PT on Curis (CRIS) to $9; Erivedge Phase 2 Misses Roche's (RHHBY) Internal Expectations
-
Palatin Technologies (PTN) is Ready to Soar; Roth Reaffirms 'Buy' Rating
-
Synta Pharma (SNTA) Positive Trajectory Reinforced by Latest ENCHANT-1 Data - Roth
-
Roth on Sidelines with Yingli Green Energy (YGE); Leverage Will Continue to Limit Upside
-
Applied Optoelectronics (AAOI) Prices 3M Common Follow-On at $24.25/Share
-
Applied Optoelectronics Announces Pricing of Follow-on Public Offering
-
Roth Capital Starts Concert Pharmaceuticals (CNCE) at Buy
-
Roth Lifts PT on SolarCity (SCTY) to $80; Notes GAAP Measures are Often Underestimated
-
Roth Still Bullish on Ligand Pharma (LGND) Following NOXAFIL Approval (MRK)
-
Roth Cuts PT on Galena Biopharma (GALE) on SEC Risk
-
Roth Reaffirms Peregrine Pharma (PPHM) at Buy; Prelim. Bavituximab + Sorafenib Phase I/II is Positive
-
Roth Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until ICT-107 Picture Clears
-
Notable Analyst Rating Changes 03/14: (TEVA) (SIRI) (LOW) Upgraded; (PLUG) (XOXO) (NUE) Downgraded
-
Roth Keeps Keryx Biopharma (KERX) at Buy; Zerenex Potential Remains Strong
-
Pre-Open Stock Movers 3/14: (HART) (MEET) (LMCA) Higher; (ARO) (ZBB) (PLUG) Lower (more...)
-
Roth Capital Downgrades Plug Power (PLUG) to Neutral
-
GenVec (GNVC) to Place $9M of Common at $3.15/Share
-
TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor
-
OXiGENE Announces Updated Time for Presentation at the ROTH Conference
-
Roth Boosts PT on Hydrogenics (HYGS) to $40; P2G Will Eventually Provide Long-Term Growth
-
Key Takeaways From ROTH 2014 OC Conference (SCTY) (CSIQ) (JASO)

